Vivos Therapeutics price target lowered to $1.75 from $2.50 at Alliance Global

Alliance Global lowered the firm’s price target on Vivos Therapeutics (VVOS) to $1.75 from $2.50 and keeps a Neutral rating on the shares. Vivos Therapeutics reported Q4 results that were significantly weaker than the prior quarter, with revenues missing expectations and expenses slightly higher, the analyst tells investors in a research note. Management cited provider work interruptions as a key driver of the shortfall, expects improvement beginning in Q1 with a stronger recovery in Q2, and may need to strengthen its balance sheet, making the quarter a setback overall, the firm says.